Focus: Sironax is a Beijing-based biotech founded in 2017 focused on therapies targeting the root cause of age-related degenerative diseases, particularly neurodegenerative conditions. The company operates at a modest scale of 51-200 employees with early-stage clinical programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Sironax presents an early-stage opportunity for risk-tolerant scientists seeking hands-on involvement in novel aging biology, but limited pipeline depth, funding transparency, and publication record require due diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sironax
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sironax's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo